Pioglitazone

Immunotag™ SFRS6 Antibody-Biotin*

Latanoprost is an F-series PG analog which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester, a prodrug form which is converted to latanoprost (free acid) by endogenous esterase enzymes.

Latanoprost is an F-series PG analog which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester, a prodrug form which is converted to latanoprost (free acid) by endogenous esterase enzymes.

Latanoprost is an F-series PG analog which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester, a prodrug form which is converted to latanoprost (free acid) by endogenous esterase enzymes.

Latanoprost is an F-series PG analog which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester, a prodrug form which is converted to latanoprost (free acid) by endogenous esterase enzymes.

General description LATS2 is a serine/threonine protein kinase belonging to the LATS tumor suppressor family. The kinase activity and two conserved domains within LATS2 are responsible for the suppression of tumorigenicity and inhibition of cell

A potent inhibitor of EGFR-associated tyrosine kinase with an IC50 value of 0.012 &microM that also inhibits pp60c-src(+) kinase and CamKII with IC50 values of 0.5 and 0.2 &microM, respectively.

Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding,

Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding,

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC 50 =47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC 50 s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC 50 =47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC 50 s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC 50 =47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC 50 s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC